婴儿结核硬化综合体多重复发性脑膜上高心率:需要三重药物治疗的管理
Xander Jacquemyn1,2, Shelby Kutty1, Mitchell I Cohen3
1Department of Pediatrics, Helen B. Taussig Heart Center, Johns Hopkins Hospital, Baltimore, MD, USA.
Cardiology in the young
|May 24, 2024
概括
一个患有结核性硬化综合体的新生儿经历了由于心脏狂宫肌瘤而导致的复发性脑上脉上高心力衰竭. 三重药物治疗成功地控制了这种情况,突出了这种心律失常的罕见结构原因.
科学领域:
- 心脏病学 心脏病学
- 遗传学 遗传学 是一个
- 新生儿科学 新生儿科学
背景情况:
- 结核性硬化综合体 (TSC) 是一种遗传性疾病,可以影响多个器官,包括心脏.
- 心脏类拉布多米奥马是婴儿和儿童中最常见的心脏瘤,通常与TSC有关.
- 上心室性心跳动 (SVT) 是新生儿常见的心律障碍,但很少与心脏结构异常有关.
研究的目的:
- 报告一例罕见的带性硬化综合体和心脏狂宫瘤的新生儿中脑膜上下心跳的罕见病例.
- 在结构性心脏异常的背景下突出SVT的诊断挑战和管理策略.
- 讨论隐藏的辅助路径在TSC相关的SVT中的潜在作用.
主要方法:
- 多模式成像 (心声学,MRI) 用于心脏评估.
- 对结核性硬化综合体进行遗传检测.
- 临床监测复发的 supraventricular 高心率.
- 药物管理包括一线和随后的三重药物治疗.
主要成果:
- 结核性硬化综合体的诊断证实在一个患有心脏狂宫肌瘤的女新生儿身上.
- 顺利治疗中心上高心率的初始发作.
- 发生了重复的脑上垂体心力衰竭,对一线治疗没有反应.
- 三重药物治疗实现了稳定性,并防止了进一步的SVT复发.
结论:
- 在新生儿中,由于心脏狂宫瘤而导致结核性硬化综合体的上心室性心力衰竭可能发生.
- 在这种人群中,SVT的管理可能需要积极的,多种药物的方法.
- 在耐火的情况下,应考虑多个隐藏的辅助路径的可能性.
相关概念视频
Pulmonary Tuberculosis V
177
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
177
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
972
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
972
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
823
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
823
Disturbances in Heart Rhythm
936
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
936
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Desensitization and Tachyphylaxis
1.7K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.7K


